Document is current
Any future updates will be listed below
-
Authors
Bug, Gesine https://orcid.org/0000-0003-2359-131X
Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Niittyvuopio, Riitta
Stelljes, Matthias https://orcid.org/0000-0002-9331-5145
Reinhardt, Hans Christian
Hilgendorf, Inken https://orcid.org/0000-0003-2038-9730
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Kaare, Ain https://orcid.org/0000-0002-3170-1016
Bethge, Wolfgang https://orcid.org/0000-0001-6052-2618
Schäfer-Eckart, Kerstin
Verbeek, Mareike
Mielke, Stephan
Carlson, Kristina
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Savani, Bipin N.
Nagler, Arnon https://orcid.org/0000-0002-0763-1265
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
- License Information
-
More Information
Article History
Received: 9 August 2022
Revised: 13 March 2023
Accepted: 17 March 2023
First Online: 31 March 2023
Competing interests
: GB received research support from Novartis and honoraria and travel expenses from Jazz, Celgene, Novartis, and Gilead. HCR received consulting and lecture fees from Abbvie, AstraZeneca, Vertex, Novartis and Merck and research funding from Gilead Pharmaceuticals and AstraZeneca. HCR is a co-founder of CDL Therapeutics GmbH. IH received honoraria from Novartis, ABBVIE, has obtained travel, accommodation or expenses from medac GmbH, Janssen-Ciliag, Jazz Pharmaceuticals and Celgene. WB received honoraria from Miltenyi, Celgene, Gilead und Novartis and travel exprenses from Medac. All other authors declare no conflict of interest.
: This study was approved by the ALWP of the EBMT institutional review board and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
: All patients gave informed consent authorizing the use of their personal information for research purposes.
